Interstitial Cystitis Market Size is Expected to grow at a CAGR of 4% by 2034

The Interstitial Cystitis market size in the 7MM was valued at USD 3 billion in 2024 and is expected to expand at a notable CAGR of 4% over the forecast period from 2025 to 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Interstitial Cystitis landscape.

In 2024, Germany recorded the largest market size for Interstitial Cystitis within the EU4 and the UK, estimated at around USD 300 million, followed by the UK at approximately USD 200 million. In Japan, the Interstitial Cystitis market was valued at about USD 60 million in 2024.

In 2024, there were an estimated 11 million prevalent cases of Interstitial Cystitis across the 7MM, underscoring the substantial disease burden and the need for better diagnostics and more effective therapies. Within the EU4 and the UK, case distribution in 2024 showed around 50% classified as moderate, 35% as mild, and 15% as severe, highlighting that moderate cases account for the majority of the clinical burden.

In 2024, the greatest prevalence of Interstitial Cystitis in the US was observed among individuals aged 56–74, with around 900,000 cases, followed by approximately 700,000 cases in the 36–55 age group, emphasizing the increasing disease impact among middle-aged and older populations.

In 2024, females accounted for about 60% of Interstitial Cystitis cases in the US, compared to 40% in males. This notable gender gap highlights the higher disease burden among women and underscores the importance of gender-specific research and treatment approaches.

DelveInsight’s report “Interstitial Cystitis Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Interstitial Cystitis landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

To Know in detail about the Interstitial Cystitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Interstitial Cystitis Market Forecast

Some of the key facts of the Interstitial Cystitis Market Report: 

• Key Interstitial Cystitis Companies: Johnson & Johnson, KYORIN Pharmaceuticals, Vaneltix Pharma/Hyloris Pharma, Ono Pharmaceutical, Seikagaku Corporation, Imbrium Therapeutics, Aska Pharmaceutical, UCB Pharma, Imbrium Therapeutics, PureTech Health, Seikagaku Corporation, Ironwood Pharmaceuticals, Inc., Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Allergan, Vaneltix Pharma, Inc./Prevail Infoworks, Inc, and others
• Key Interstitial Cystitis Therapies: ELMIRON (pentosan polysulfate sodium), ZYMSO (Dimethyl Sulfoxide), ALENURA (Lidocaine + Heparin), ONO-1110, SI-722, Sunobinop (V117957), AKP-021, Certolizumab pegol, Sunobinop, IMB 150, SI-722, IW-3300, Peppermint oil, Ferumoxytol, BOTOX, VNX001, and others
• Delvelnsight has also examined Interstitial Cystitis type-specific statistics. Based on this information, IC can be classified as either non-ulcerative or ulcerative. According to research, there were 1,410,434 instances of the non-ulcerative and 156,715 cases of the ulcerative form of Interstitial Cystitis in the United States in 2021.
• The Interstitial Cystitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Interstitial Cystitis pipeline products will significantly revolutionize the Interstitial Cystitis market dynamics.

Interstitial Cystitis Overview

Interstitial Cystitis (IC), commonly known as Painful Bladder Syndrome, is a chronic illness that causes pelvic pain occasionally as well as bladder pressure and pain. The pain can be mildly uncomfortable or extremely painful. Most people experience the need to urinate because the bladder, a hollow, muscular organ that collects urine, swells until it is full and then sends signals to the brain that it is time to urinate through the pelvic nerves.

Get a Free sample for the Interstitial Cystitis Market Report:

https://www.delveinsight.com/report-store/interstitial-cystitis-market-forecast

Interstitial Cystitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Interstitial Cystitis Epidemiology Segmentation:

The Interstitial Cystitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Prevalent Cases of Interstitial Cystitis in the 7MM
• Total Diagnosed Prevalent Cases of Interstitial Cystitis in the 7MM
• Age-specific Cases of Interstitial Cystitis in the 7MM
• Total Treated Cases of Interstitial Cystitis in the 7MM
• Type-specific Cases of Interstitial Cystitis in the 7MM
• Severity-specific Cases of Interstitial Cystitis in the 7MM

Download the report to understand which factors are driving Interstitial Cystitis epidemiology trends @ Interstitial Cystitis Epidemiology Forecast

Recent Developments In The Treatment Landscape:

• In March 2025, Imbrium Therapeutics, a subsidiary of Purdue Pharma, announced the completion of the final patient visit in its Phase 1b clinical trial (NCT06285214) assessing the investigational oral therapy sunobinop (V117957) for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS).
• In March 2025, Hyloris reported a favorable interim review for its ALENURA clinical trial, with the Independent Data Monitoring Committee (IDMC) recommending the study’s continuation. Patient enrollment is anticipated to conclude by the end of 2025. ALENURA is being developed as a potential first-line therapy for interstitial cystitis.
• In April 2024, Glycologix, Inc. (“Glycologix”), a clinical-stage biopharma company specializing in biopolymer therapies for soft tissue protection and repair, announced that results from its multi-center Phase 1b trial of GLX-100 in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) will be presented at the 2025 American Urological Association (AUA) Annual Meeting.

Interstitial Cystitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Interstitial Cystitis market or expected to get launched during the study period. The analysis covers Interstitial Cystitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Interstitial Cystitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Interstitial Cystitis Therapies and Key Companies

• ELMIRON (pentosan polysulfate sodium): Johnson & Johnson
• ZYMSO (Dimethyl Sulfoxide): KYORIN Pharmaceuticals
• ALENURA (Lidocaine + Heparin): Vaneltix Pharma/Hyloris Pharma
• ONO-1110: Ono Pharmaceutical
• SI-722: Seikagaku Corporation
• Sunobinop (V117957): Imbrium Therapeutics
• AKP-021: Aska Pharmaceutical
• Certolizumab pegol: UCB Pharma
• Sunobinop: Imbrium Therapeutics
• IMB 150: PureTech Health
• SI-722: Seikagaku Corporation
• IW-3300: Ironwood Pharmaceuticals, Inc.
• Peppermint oil: Integrative Therapeutics, Inc.
• Ferumoxytol: Lipella Pharmaceuticals, Inc.
• BOTOX: Allergan
• VNX001: Vaneltix Pharma, Inc./Prevail Infoworks, Inc

Discover more about therapies set to grab major Interstitial Cystitis market share @ Interstitial Cystitis Treatment Market

Interstitial Cystitis Market Drivers

• Rising disease prevalence due to increasing awareness and improved diagnostic rates.
• Growing female patient population, as the disease predominantly affects women.
• Advancements in diagnostic tools and biomarkers enabling early detection.
• Emergence of novel therapies and targeted treatment options improving patient outcomes.
• Increased R&D investments by pharmaceutical and biotech companies.
• Supportive government initiatives and patient advocacy programs promoting disease education.

Interstitial Cystitis Market Barriers

• Lack of specific diagnostic criteria, leading to underdiagnosis or misdiagnosis.
• Limited availability of effective and long-lasting treatments.
• High treatment costs and reimbursement challenges affecting patient access.
• Chronic and relapsing nature of the disease complicating long-term management.
• Adverse effects and limited efficacy of currently available therapies.
• Low patient compliance due to lengthy and complex treatment regimens.

Scope of the Interstitial Cystitis Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Interstitial Cystitis Companies: Johnson & Johnson, KYORIN Pharmaceuticals, Vaneltix Pharma/Hyloris Pharma, Ono Pharmaceutical, Seikagaku Corporation, Imbrium Therapeutics, Aska Pharmaceutical, UCB Pharma, Imbrium Therapeutics, PureTech Health, Seikagaku Corporation, Ironwood Pharmaceuticals, Inc., Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Allergan, Vaneltix Pharma, Inc./Prevail Infoworks, Inc, and others
• Key Interstitial Cystitis Therapies: ELMIRON (pentosan polysulfate sodium), ZYMSO (Dimethyl Sulfoxide), ALENURA (Lidocaine + Heparin), ONO-1110, SI-722, Sunobinop (V117957), AKP-021, Certolizumab pegol, Sunobinop, IMB 150, SI-722, IW-3300, Peppermint oil, Ferumoxytol, BOTOX, VNX001, and others
• Interstitial Cystitis Therapeutic Assessment: Interstitial Cystitis current marketed and Interstitial Cystitis emerging therapies
• Interstitial Cystitis Market Dynamics: Interstitial Cystitis market drivers and Interstitial Cystitis market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Interstitial Cystitis Unmet Needs, KOL’s views, Analyst’s views, Interstitial Cystitis Market Access and Reimbursement 
   

To know more about Interstitial Cystitis companies working in the treatment market, visit @ Interstitial Cystitis Clinical Trials and Therapeutic Assessment